| pubmed-article:17555368 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17555368 | lifeskim:mentions | umls-concept:C0346647 | lld:lifeskim |
| pubmed-article:17555368 | lifeskim:mentions | umls-concept:C0037083 | lld:lifeskim |
| pubmed-article:17555368 | lifeskim:mentions | umls-concept:C1710082 | lld:lifeskim |
| pubmed-article:17555368 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:17555368 | pubmed:dateCreated | 2007-6-8 | lld:pubmed |
| pubmed-article:17555368 | pubmed:abstractText | Pancreatic cancer remains a treatment-refractory cancer. Standard therapy for metastatic cancer is gemcitabine chemotherapy, with a median survival of 5-6 months. The epidermal growth factor receptor (EGFR) is commonly expressed in pancreatic cancer and has been evaluated as a therapeutic target. A Phase III trial of gemcitabine with or without the EGFR inhibitor, erlotinib, demonstrated a modest but significant prolongation of survival with the addition of erlotinib. A Phase II trial of gemcitabine with the anti-EGFR antibody cetuximab resulted in a 1-year survival of 32%. A Phase III trial of gemcitabine with or without cetuximab and a randomized Phase II trial of the Murren regimen with or without cetuximab are completed; results for both are anticipated in 2007. A Phase I trial of gemcitabine with the EGFR/Her-2 inhibitor, lapatinib, is completed. Improved patient selection and rational combination of targeted therapies will be necessary to optimize the management of patients with this tragic disease. | lld:pubmed |
| pubmed-article:17555368 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17555368 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17555368 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17555368 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17555368 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17555368 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17555368 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17555368 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17555368 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17555368 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17555368 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17555368 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17555368 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17555368 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17555368 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17555368 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17555368 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17555368 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:17555368 | pubmed:issn | 1744-7682 | lld:pubmed |
| pubmed-article:17555368 | pubmed:author | pubmed-author:BurtnessBarba... | lld:pubmed |
| pubmed-article:17555368 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:17555368 | pubmed:volume | 7 | lld:pubmed |
| pubmed-article:17555368 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17555368 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17555368 | pubmed:pagination | 823-9 | lld:pubmed |
| pubmed-article:17555368 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:17555368 | pubmed:meshHeading | pubmed-meshheading:17555368... | lld:pubmed |
| pubmed-article:17555368 | pubmed:meshHeading | pubmed-meshheading:17555368... | lld:pubmed |
| pubmed-article:17555368 | pubmed:meshHeading | pubmed-meshheading:17555368... | lld:pubmed |
| pubmed-article:17555368 | pubmed:meshHeading | pubmed-meshheading:17555368... | lld:pubmed |
| pubmed-article:17555368 | pubmed:meshHeading | pubmed-meshheading:17555368... | lld:pubmed |
| pubmed-article:17555368 | pubmed:meshHeading | pubmed-meshheading:17555368... | lld:pubmed |
| pubmed-article:17555368 | pubmed:meshHeading | pubmed-meshheading:17555368... | lld:pubmed |
| pubmed-article:17555368 | pubmed:meshHeading | pubmed-meshheading:17555368... | lld:pubmed |
| pubmed-article:17555368 | pubmed:meshHeading | pubmed-meshheading:17555368... | lld:pubmed |
| pubmed-article:17555368 | pubmed:meshHeading | pubmed-meshheading:17555368... | lld:pubmed |
| pubmed-article:17555368 | pubmed:meshHeading | pubmed-meshheading:17555368... | lld:pubmed |
| pubmed-article:17555368 | pubmed:meshHeading | pubmed-meshheading:17555368... | lld:pubmed |
| pubmed-article:17555368 | pubmed:meshHeading | pubmed-meshheading:17555368... | lld:pubmed |
| pubmed-article:17555368 | pubmed:meshHeading | pubmed-meshheading:17555368... | lld:pubmed |
| pubmed-article:17555368 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17555368 | pubmed:articleTitle | Her signaling in pancreatic cancer. | lld:pubmed |
| pubmed-article:17555368 | pubmed:affiliation | Fox Chase Cancer Center, Department of Medical Oncology, Division of Medical Science, Philadelphia, PA 19111, USA. barbara.burtness@fccc.edu | lld:pubmed |
| pubmed-article:17555368 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17555368 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17555368 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17555368 | lld:pubmed |
